Intuitive Surgical Reports Strong 2025 Financial Results, Driven by Procedure Growth and New Product Launches
ISRG is trading near its 52-week low of $425 (13% above the low) on elevated volume (2.0× avg).
Summary
Intuitive Surgical reported strong 2025 financial results with significant revenue and net income growth, driven by increased procedure volumes, new product launches, and a substantial share repurchase program.
Key Events · Earnings and Guidance · ISRG
-
Strong Financial Performance in 2025
Total revenue increased by 21% to $10.06 billion, net income attributable to Intuitive Surgical, Inc. grew 23% to $2.86 billion, and diluted EPS rose 22.6% to $7.87, demonstrating robust financial health.
-
Significant Procedure Volume Growth
da Vinci procedures increased by 18% to 3.15 million, and Ion procedures surged 51% to 144,100, reflecting strong adoption of robotic-assisted surgeries and diagnostics.
-
Expanded System Placements and Installed Base
The company placed 1,721 da Vinci surgical systems (13% increase), including 870 of the new da Vinci 5 systems, growing the total installed base to over 11,100 systems. Ion system installed base also grew 24% to 995 systems.
-
Strategic Product Development and Regulatory Clearances
Numerous new regulatory clearances were obtained for da Vinci 5 (including cardiac procedures), SP surgical systems (new surgical indications), and AI-integrated software for the Ion endoluminal system, enhancing product offerings and market reach.
Analysis · ISRG · Industrial Applications And Services
Intuitive Surgical's 2025 annual report details robust financial and operational performance, significantly exceeding prior year results. The company achieved substantial revenue and net income growth, driven by increased procedure volumes for both da Vinci and Ion systems, and expanded its installed base globally. Strategic moves include the launch of the fifth-generation da Vinci 5 surgical system and numerous new regulatory clearances for its products, including AI-integrated software for the Ion system. A significant share repurchase program was also active during the year, returning capital to shareholders. While the report outlines ongoing legal challenges and macroeconomic risks, the overall picture is one of strong growth and continued innovation in the robotic-assisted surgery market.
At the time of this filing, ISRG was trading at $479.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $169.8B. The 52-week trading range was $425.00 to $609.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.